148 related articles for article (PubMed ID: 32580307)
1. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.
Dókus LE; Lajkó E; Ranđelović I; Mező D; Schlosser G; Kőhidai L; Tóvári J; Mező G
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32580307
[TBL] [Abstract][Full Text] [Related]
2. Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
Tripodi AAP; Tóth S; Enyedi KN; Schlosser G; Szakács G; Mező G
Beilstein J Org Chem; 2018; 14():911-918. PubMed ID: 29765472
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract][Full Text] [Related]
4. Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
Kiss K; Biri-Kovács B; Szabó R; Ranđelović I; Enyedi KN; Schlosser G; Orosz Á; Kapuvári B; Tóvári J; Mező G
Eur J Med Chem; 2019 Aug; 176():105-116. PubMed ID: 31100648
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH-Peptide Conjugates.
Szabó I; Biri-Kovács B; Vári B; Ranđelović I; Vári-Mező D; Juhász É; Halmos G; Bősze S; Tóvári J; Mező G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256168
[TBL] [Abstract][Full Text] [Related]
6. Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.
Lajkó E; Spring S; Hegedüs R; Biri-Kovács B; Ingebrandt S; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():2495-2509. PubMed ID: 30344773
[No Abstract] [Full Text] [Related]
7. [Comparison of therapeutic peptides targeting pancreatic cancer].
Mezõ G; Dókus L; Schlosser G; Lajkó E; Szász Z; Ranđelović I; Biri-Kovács B; Tóvári J; Kõhidai L
Magy Onkol; 2019 Dec; 63(4):301-308. PubMed ID: 31821385
[TBL] [Abstract][Full Text] [Related]
8. Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.
Polgár L; Lajkó E; Soós P; Láng O; Manea M; Merkely B; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():1583-1594. PubMed ID: 30013686
[No Abstract] [Full Text] [Related]
9. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
[TBL] [Abstract][Full Text] [Related]
10. A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro.
Orbán E; Manea M; Marquadt A; Bánóczi Z; Csík G; Fellinger E; Bosze S; Hudecz F
Bioconjug Chem; 2011 Oct; 22(10):2154-65. PubMed ID: 21950465
[TBL] [Abstract][Full Text] [Related]
11. New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells.
Miklán Z; Orbán E; Csík G; Schlosser G; Magyar A; Hudecz F
Biopolymers; 2009; 92(6):489-501. PubMed ID: 19521976
[TBL] [Abstract][Full Text] [Related]
12. Oxime-Linked Peptide-Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview.
Mező G; Gomena J; Ranđelović I; Dókus EL; Kiss K; Pethő L; Schuster S; Vári B; Vári-Mező D; Lajkó E; Polgár L; Kőhidai L; Tóvári J; Szabó I
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339141
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery.
Tripodi AAP; Ranđelović I; Biri-Kovács B; Szeder B; Mező G; Tóvári J
Pathol Oncol Res; 2020 Jul; 26(3):1879-1892. PubMed ID: 31820302
[TBL] [Abstract][Full Text] [Related]
14. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
Kapuvári B; Hegedüs R; Schulcz Á; Manea M; Tóvári J; Gacs A; Vincze B; Mező G
Invest New Drugs; 2016 Aug; 34(4):416-23. PubMed ID: 27146514
[TBL] [Abstract][Full Text] [Related]
15. [Application of Asn-Gly-Arg sequence based cyclic peptides for targeted tumor therapy].
Mező GM; Tripodi Angelo Pierluigi ATAP; Ranđelovič IR; Enyedi NKE; Biri-Kovács BB; Tóvári JT
Magy Onkol; 2021 Jun; 65(2):113-120. PubMed ID: 34081759
[TBL] [Abstract][Full Text] [Related]
16. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
[TBL] [Abstract][Full Text] [Related]
17. Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification.
Schuster S; Biri-Kovács B; Szeder B; Buday L; Gardi J; Szabó Z; Halmos G; Mező G
Pharmaceutics; 2018 Nov; 10(4):. PubMed ID: 30423956
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.
Schuster S; Biri-Kovács B; Szeder B; Farkas V; Buday L; Szabó Z; Halmos G; Mező G
Beilstein J Org Chem; 2018; 14():756-771. PubMed ID: 29719573
[TBL] [Abstract][Full Text] [Related]
19. Carboxy derivatives of isoflavones as affinity carriers for cytotoxic drug targeting in adrenocortical H295R carcinoma cells.
Somjen D; Stern N; Knoll E; Sharon O; Gayer B; Kulik T; Kohen F
J Endocrinol; 2003 Dec; 179(3):395-403. PubMed ID: 14656209
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
